CSL Limited (CMXHF) Stock Analysis & Winston Score

CSL Limited is a large Australian biotechnology company that collects human blood plasma and turns it into life-saving medicines. These medicines treat rare and serious conditions like immune deficiencies, bleeding disorders such as hemophilia, and neurological diseases. CSL also makes influenza vaccines through its Seqirus division, which is one of the largest flu vaccine businesses in the world. CSL earns most of its revenue by selling plasma-derived therapies and vaccines to hospitals, clinics, and healthcare systems across more than 100 countries. The company operates its own network of plasma collection centers, mostly in the United States, which gives it a significant cost and supply advantage over smaller rivals. Its main growth driver is rising global demand for immunoglobulin therapies, but the business faces ongoing pressure from high plasma collection costs and competition from other large plasma companies like Grifols and Takeda's Baxalta unit.